Suvanza SUVZ
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.50
- Shares Outstanding
- 111,969.00
- Market Cap
- $22.39
- Volume/Avg
- 219 / 216
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Suvanza is a biotechnology company which develops products for skin, hair, and nails diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 17
- Website
- http://www.suvanza.com
Valuation
|
Metric
|
SUVZ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SUVZ
|
|---|---|
Quick Ratio | 0.23 |
Current Ratio | 0.89 |
Interest Coverage | — |
Quick Ratio
No chart available
Profitability
|
Metric
|
SUVZ
|
|---|---|
Return on Assets (Normalized) | −141.94% |
Return on Equity (Normalized) | −171.33% |
Return on Invested Capital (Normalized) | −170.55% |
Return on Assets
No chart available
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|H?#$z%c | LOCK|SK$%P | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|HT<@v@ | LOCK|@@nGM | $83B | |||
| Moderna Inc
MRNA
| LOCK|mtvDVNF | LOCK|T& | $80B | |||
| argenx SE ADR
ARGX
| LOCK|??ZXWpz | LOCK|cFx | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$WV!qMP | LOCK|rD | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|D&mbF$W | LOCK|&&^V | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&<MB%@rT | LOCK|>^c<Q | $28B | |||
| Incyte Corp
INCY
| LOCK|<%#RDf# | LOCK|$QB | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|FHm#SCY | LOCK|x@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?@qZ@s | LOCK|bQM | $14B |